Rubin Guo
Adult Health · Stony Brook, NYNPI 1942435417
Payments from drug & device makers
Across 38 payments — averaging $46.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$305
- Seagen Inc.$242
- GSK$218
- Astellas Pharma US Inc$148
- Regeneron Healthcare Solutions, Inc.$125
- Johnson & Johnson$124
- plus $599 from 16 others
What the payments were for
- Consulting fees$1006%
- Food & beverage$1,31575%
- Education$34720%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 3 | $305 |
| Seagen Inc. | 2 | $242 |
| GSK | 2 | $218 |
| Astellas Pharma US Inc | 3 | $148 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Johnson & Johnson | 1 | $124 |
| Kyowa Kirin, Inc. | 4 | $80 |
| Pfizer | 4 | $72 |
| Daiichi Sankyo Inc. | 3 | $68 |
| Sanofi-aventis U.S. LLC | 2 | $60 |
| AstraZeneca | 1 | $43 |
| Novartis | 2 | $43 |
| Agios Pharmaceuticals, Inc. | 1 | $27 |
| Pharmaessentia USA Corporation | 1 | $27 |
| Melinta Therapeutics, LLC | 1 | $27 |
| Genmab U.S., Inc. | 1 | $27 |
| Geron Corporation | 1 | $26 |
| Regeneron | 1 | $25 |
| Bristol Myers Squibb | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Gamida Cell Inc. | 1 | $17 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,762 in reported general payments places this provider in the 75th percentile of 3,828 adult health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 21 | $334,737 |
| BrukinsaZanubrutinib | 15 | $207,057 |
| EliquisApixaban | 19 | $12,832 |
| Imatinib Mesylate | 11 | $8,107 |
| Acyclovir | 49 | $762 |
| Allopurinol | 25 | $139 |
| Omeprazole | 15 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $25 | $334,73721 claims |
| PfizerEliquis | $72 | $12,83219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,828 adult health providers in New York.
Other adult health in Stony Brook
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Katelyn McCormackAmherst$201K
- Mary CiechoskiBuffalo$200K
- Patricia LorussoLancaster$161K
- Jennifer FioriniGlens Falls$151K
- Tia AlbroRochester$142K
- Maria Gigante-BaggettEast Syracuse$92K
- Jane PattersonRochester$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.